Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Jade Biosciences, Inc.

Get SEC filing alerts via email and in your feed for Jade Biosciences, Inc.

JBIO

Jade Biosciences, Inc.

About Jade Biosciences, Inc.

Aerovate Therapeutics, Inc. is a biopharmaceutical company focused on developing inhaled therapies for pulmonary arterial hypertension (PAH), a rare and serious lung disease. Its primary product candidate was AV-101, a dry powder inhaled formulation of imatinib designed to target abnormal cellular proliferation in pulmonary arteries. The company’s business model centers on drug development, clinical trials, and regulatory approval processes targeting PAH patients in the U.S. and Europe.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Jade Biosciences, Inc.

1
1
Jade Biosciences, Inc. Jade Biosciences Reports $40.4 Million Net Loss in Q1 2026 Amid Rising Expenses

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Jade Biosciences, Inc. Jade Biosciences Reports Significant Increase in Operating Expenses and Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Jade Biosciences, Inc. Jade Biosciences Reports $25.2 Million Net Loss in Q3 2025, Highlights Strategic Financing and Product Development

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Jade Biosciences, Inc. Jade Biosciences Reports $32.1 Million Net Loss in Latest Quarter, Focuses on R&D for Autoimmune Therapies

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Jade Biosciences, Inc. Aerovate Therapeutics Reports Reduced Losses and Cash Increase Amid Merger with Jade Biosciences

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Jade Biosciences, Inc. Aerovate Therapeutics Reports $69.6M Net Loss, Plans Merger with Jade Biosciences

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Jade Biosciences, Inc. Aerovate Therapeutics Reports Net Loss of $16.2M, Announces Merger Agreement with Jade Biosciences

Via official filing (AI summary) | over 1 year ago | 0 comments